Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss

Journal of Bone and Mineral Research

Volumn 24, Issue 7, 2009, Pages 1194-1205

  Tomimori, Yoshiya ^a   Mori, Kaoru ^a   Koide, Masanori ^b   Nakamichi, Yuko ^b   Ninomiya, Tadashi ^b   Udagawa, Nobuyuki ^b   Yasuda, Hisataka ^a  

^a Oriental Yeast Co Ltd   (Japan)

^b MATSUMOTO DENTAL UNIVERSITY   (Japan)

Author keywords

Animal model; Bisphosphonates; Osteoporosis; PTH PTH related peptide; Selective estrogen receptor modulators

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; DRUG; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; FEMALE; MORPHOMETRICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; THREE DIMENSIONAL IMAGING; TRABECULAR BONE;

ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CELL DIFFERENTIATION; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; MICE; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; PARATHYROID HORMONE; RANK LIGAND; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TIME FACTORS;

EID: 70349116967     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.090217     Document Type: Article

References (37)

1. Rodan GA, Martin TJ 2000 Therapeutic approaches to bone diseases. Science 289:1508-1514.
2. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for post-menopausal osteoporosis. Endocr Rev 23:570-578. (Pubitemid 34925651)
3. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R 1993 Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690-709. (Pubitemid 24016657)
4. Bilezikian JP, Raisz LG, Rodan GA 2002 Principles of Bone Biology, 2nd ed., vol.2. Academic Press, San Diego, CA, USA.
5. Kalu DN, Liu CC, Hardin RR, Hollis BW 1989 The aged rat model of ovarian hormone deficiency bone loss. Endocrinology 124:7-16.
6. Anderson JJ, Garner SC, Mar MH, Boass A, Toverud SU, Parikh I 1990 The ovariectomized, lactating rat as an experimental model for osteopenia: Calcium metabolism and bone changes. Bone Miner 11:43-53. (Pubitemid 20340687)
7. Sessions ND, Halloran BP, Bikle DD, Wronski TJ, Cone CM, Morey-Holton E 1989 Bone response to normal weight bearing after a period of skeletal unloading. Am J Physiol 257:E606-E610. (Pubitemid 19263388)
8. Dehority W, Halloran BP, Bikle DD, Curren T, Kostenuik PJ, Wronski TJ, Shen Y, Rabkin B, Bouraoui A, Morey-Holton E 1999 Bone and hormonal changes induced by skeletal unloading in the mature male rat. Am J Physiol 276:E62-E69. (Pubitemid 29065594)
9. Wakley GK, Baum BL, Hannon KS, Turner RT 1988 The effects of tamoxifen on the osteopenia induced by sciatic neurotomy in the rat: A histomorphometric study. Calcif Tissue Int 43:383-388.
10. Broulik PD 1991 Tamoxifen prevents bone loss in ovariectomized mice. Endocr Regul 25:217-219.
11. Turner RT, Vandersteenhoven JJ, Bell NH 1987 The effects of ovariectomy and 17 beta-estradiol on cortical bone histomorphometry in growing rats. J Bone Miner Res 2:115-122.
12. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K 1997 Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:137-142.
13. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329-1337. (Pubitemid 28510154)
14. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602. (Pubitemid 28173173)
15. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319. (Pubitemid 27199902)
16. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176. (Pubitemid 28180851)
17. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS, Frankel WN III, Lee SY, Choi Y 1997 TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272:25190-25194. (Pubitemid 27415705)
18. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179. (Pubitemid 27507987)
19. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K 1998 RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253:395-400. (Pubitemid 29026714)
20. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ 1999 Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540-3545. (Pubitemid 29168945)
21. Horwood NJ, Elliott J, Martin TJ, Gillespie MT 1998 Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139:4743-4746. (Pubitemid 28487795)
22. Maruyama K, Takada Y, Ray N, Kishimoto Y, Penninger JM, Yasuda H, Matsuo K 2006 Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice. J Immunol 177:3799-3805. (Pubitemid 44359913)
23. Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, Schwarz T, Penninger JM, Beissert S 2006 Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 12:1372-1379. (Pubitemid 44924495)
24. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323. (Pubitemid 29061638)
25. Yamamoto Y, Udagawa N, Matsuura S, Nakamichi Y, Horiuchi H, Hosoya A, Nakamura M, Ozawa H, Takaoka K, Penninger JM, Noguchi T, Takahashi N 2006 Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand. Endocrinology 147:3366-3374. (Pubitemid 43901128)
26. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T 2000 Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191:275-286. (Pubitemid 30060917)
27. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL 1999 The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527-538. (Pubitemid 29215717)
28. Ito M, Nakayama K, Konaka A, Sakata K, Ikeda K, Maruyama T 2006 Effects of a prostaglandin EP4 agonist, ONO-4819, and risedronate on trabecular microstructure and bone strength in mature ovariectomized rats. Bone 39:453-459.
29. Ebbesen EN, Thomsen JS, Mosekilde L 1997 Nondestructive determination of iliac crest cancellous bone strength by pQCT. Bone 21:535-540. (Pubitemid 28029697)
30. Schmidt C, Priemel M, Kohler T, Weusten A, Muller R, Amling M, Eckstein F 2003 Precision and accuracy of peripheral quantitative computed tomography (pQCT) in the mouse skeleton compared with histology and microcomputed tomography (microCT). J Bone Miner Res 18:1486-1496. (Pubitemid 41070803)
31. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
32. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termin JD 1994 Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69. (Pubitemid 24030821)
33. Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, Takai T, Kodama T, Morio T, Geha RS, Kitamura D, Kurosaki T, Ellmeier W, Takayanagi H 2008 Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 132:794-806. (Pubitemid 351312796)
34. Ohyama Y, Nemoto H, Rittling S, Tsuji K, Amagasa T, Denhardt DT, Nifuji A, Noda M 2004 Osteopontin-deficiency suppresses growth of B16 melanoma cells implanted in bone and osteoclastogenesis in co-cultures. J Bone Miner Res 19:1706-1711. (Pubitemid 41094334)
35. Martin TJ, Sims NA 2005 Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:76-81. (Pubitemid 40193486)
36. Yuan YY, Kostenuik PJ, Ominsky MS, Morony S, Adamu S, Simionescu DT, Basalyga DM, Asuncion FJ, Bateman TA 2008 Skeletal deterioration induced by RANKL infusion: A model for high-turnover bone disease. Osteoporos Int 19:625-635.
37. Yasuda H, Furuya Y, Tomimori Y, Mori K, Miyazaki J, Enomoto T 2008 Establishment of a Murine Model of Hypercalcemia by Overexpression of sRANKL Using an Adenovirus Vector. J Bone Miner Res 23:S262.